Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

Clinical trial NCT07387198 · RECRUITING

Trial details

NCT number: NCT07387198
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Merkel Cell Carcinoma, Stage I Merkel Cell Carcinoma, Stage II Neoadjuvant Immunotherapy

Start date: 2026-05-29
Primary completion: 2029-12-31
Enrollment: 135

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.